

**Table 2** Quality assessments of the included studies

NOS(case control studies)	Selection				1 <sup>P+Q</sup>	Comparability			Exposure			Score
	1 <sup>L</sup>	2 <sup>M</sup>	3 <sup>N</sup>	4 <sup>O</sup>		1 <sup>R</sup>	2 <sup>S</sup>	3 <sup>T</sup>				
1	2016,Mengel D,Germany <sup>[1]</sup>	1	1	1	1	2	1	1	1	1	9	
2	2014,Singh NK,India <sup>[2]</sup>	1	0	1	1	2	1	1	1	1	8	
3	2013,Gregório ML,Brazil <sup>[3]</sup>	1	0	0	1	2	1	1	0	0	6	
4	2013,Dong X,China(in Chinese) <sup>[4]</sup>	1	0	0	1	2	1	1	1	1	7	
5	2011,Pulkes T,Thailand <sup>[5]</sup>	1	0	0	1	1	1	1	1	1	6	
6	2011,Kiyohara C,Japan <sup>[6]</sup>	1	1	0	1	2	1	1	0	0	7	
7	2011,Gao J,USA <sup>[7]</sup>	1	1	1	1	2	1	1	1	1	9	
8	2010,Vefring H,Norway <sup>[8]</sup>	1	0	0	1	2	1	1	1	1	7	
9	2010,Ryu HG,Korea <sup>[9]</sup>	1	0	1	1	2	1	1	1	1	8	
10	2009,Williams-Gray CH,UK <sup>[10]</sup>	1	0	1	1	1	1	1	1	0	6	
11	2009,Kurz MW,Norway <sup>[11]</sup>	1	0	0	1	1	1	1	1	1	6	
12	2009,Gallegos-Arreola MP, México <sup>[12]</sup>	1	0	1	1	2	1	1	1	1	8	
13	2008,Ezquerra M,Spain <sup>[13]</sup>	1	0	0	1	1	1	1	1	1	6	
14	2007,Papapetropoulos S,USA <sup>[14]</sup>	1	0	0	1	1	1	1	1	1	6	
15	2007,López M,Mexico <sup>[15]</sup>	1	0	1	1	1	1	1	1	1	7	
16	2007,Jasinska-Myga B,Poland <sup>[16]</sup>	1	0	0	1	2	1	1	1	1	7	
17	2007,Buchanan DD,Australia <sup>[17]</sup>	1	0	1	1	2	1	1	1	1	8	
18	2006,Tröster AI,USA <sup>[18]</sup>	1	0	0	1	1	1	1	1	1	6	
19	2006,Ghebremedhin E,Germany <sup>[19]</sup>	1	0	0	1	1	1	1	1	1	6	
20	2006,Blázquez L,Spain <sup>[20]</sup>	1	0	0	1	2	1	1	1	1	7	
21	2005,Camicioli R,Canada <sup>[21]</sup>	1	0	0	1	2	1	1	1	1	7	
22	2004,Zhou CW,China(in Chinese) <sup>[22]</sup>	1	0	0	1	1	1	1	1	1	6	
23	2003,Zhao XP,China(in Chinese) <sup>[23]</sup>	1	0	1	1	1	1	1	1	1	7	
24	2003,Schulte T,Germany <sup>[24]</sup>	1	0	0	1	2	1	1	0	0	6	
25	2002,Tang G,China <sup>[25]</sup>	1	0	1	1	2	1	1	1	1	8	
26	2002,Parsian A,USA <sup>[26]</sup>	1	0	0	1	2	1	1	0	0	6	
27	2002,Eerola J,Finland <sup>[27]</sup>	1	0	0	1	2	1	1	1	1	7	
28	2001,Wang F,China(in Chinese) <sup>[28]</sup>	1	0	1	1	1	1	1	1	1	7	
29	2001,Hao YX,China(in Chinese) <sup>[29]</sup>	1	0	0	1	1	1	1	1	1	6	
30	2000,Zeng XY,China(in Chinese) <sup>[30]</sup>	1	0	0	1	1	1	1	1	1	6	
31	2000,Harhangi BS,Netherlands <sup>[31]</sup>	1	0	1	1	1	1	1	1	1	7	
32	1999,Zhang JH,China(in CHinese) <sup>[32]</sup>	1	0	0	1	1	1	1	1	0	5	
33	1999,Oliveri RL,Italy <sup>[33]</sup>	1	0	1	1	1	1	1	1	1	7	
34	1999,Bon MA,Netherlands <sup>[34]</sup>	1	0	0	1	1	1	1	1	1	6	
35	1998,Qin B,China(in Chinese) <sup>[35]</sup>	1	0	0	1	1	1	1	1	1	6	
36	1997,NR,France(NR:not reported) <sup>[36]</sup>	1	0	0	1	1	1	1	1	1	6	
37	1997,Ballering LA,Netherlands <sup>[37]</sup>	1	0	0	1	1	1	1	1	0	5	
38	1996,Whitehead AS,Ireland <sup>[38]</sup>	1	0	1	1	2	1	1	1	1	8	
39	1994,Rubinsztein DC,UK <sup>[39]</sup>	1	0	1	1	1	1	1	1	1	7	

<sup>L</sup>,With independent validation; <sup>M</sup>,Consecutive or obviously representative series of cases; <sup>N</sup>,Community controls; <sup>O</sup>,No history of disease; <sup>P</sup>,Study controls for *APOE* genotype; <sup>Q</sup>,Study controls for any additional factor (age); <sup>R</sup>,Ascertainment of exposure by secure record; <sup>S</sup>,Same method of ascertainment for cases and controls; <sup>T</sup>,Same non-response rate for both groups.

## Reference Number

[1] Mengel D, Dams J, Ziemek J, et al. Apolipoprotein E epsilon4 does not affect cognitive performance in patients with

- Parkinson's disease[J]. *Parkinsonism & related disorders*. 2016;29:112-6.
- [2] Singh NK, Banerjee BD, Bala K, et al. APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease[J]. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2014;35(7):1075-81.
- [3] Gregorio ML, Pinhel MA, Sado CL, et al. Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson's disease[J]. *BioMed research international*. 2013;2013:641515.
- [4] Xiang D. Apolipoprotein E polymorphism and the risk of Alzheimer's disease and Parkinson's disease[J]. *Guide of China Medicine*. 2013;1671-8194(24):206-7.
- [5] Pulkes T, Papsing C, Mahasirimongkol S, et al. Association between apolipoprotein E genotypes and Parkinson's disease[J]. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2011;18(10):1333-5.
- [6] Kiyohara C, Miyake Y, Koyanagi M, et al. APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population[J]. *Journal of neural transmission*. 2011;118(9):1335-44.
- [7] Gao J, Huang X, Park Y, et al. Apolipoprotein E genotypes and the risk of Parkinson disease[J]. *Neurobiology of aging*. 2011;32(11):2106 e1-6.
- [8] Vefring H, Haugavoll K, Tysnes OB, et al. The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study[J]. *Acta neurologica Scandinavica*. 2010;122(6):438-41.
- [9] Ryu HG, Kwon OD. Apolipoprotein E epsilon 4 allele is not associated with age at onset or MMSE of Parkinson's disease in a Korean study[J]. *Parkinsonism & related disorders*. 2010;16(9):615-7.
- [10] Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease[J]. *Journal of neurology*. 2009;256(3):493-8.
- [11] Kurz MW, Dekomien G, Nilsen OB, et al. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study[J]. *Journal of geriatric psychiatry and neurology*. 2009;22(3):166-70.
- [12] Gallegos-Arreola MP, Figuera LE, Ortiz GG, et al. Apolipoprotein E genotypes in Mexican patients with Parkinson's disease[J]. *Disease markers*. 2009;27(5):225-30.
- [13] Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease[J]. *Neuroscience letters*. 2008;448(1):20-3.
- [14] Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and ApoE in Parkinson's disease[J]. *Neuroscience letters*. 2007;414(2):141-4.
- [15] Lopez M, Guerrero J, Yescas P, et al. Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population[J]. *Movement disorders : official journal of the Movement Disorder Society*. 2007;22(3):417-20.
- [16] Jasinska-Myga B, Opala G, Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia[J]. *Archives of neurology*. 2007;64(2):261-5.
- [17] Buchanan DD, Silburn PA, Prince JA, et al. Association of APOE with Parkinson disease age-at-onset in women[J]. *Neuroscience letters*. 2007;411(3):185-8.
- [18] Troster AI, Fields JA, Paolo AM, et al. Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease[J]. *Journal of the neurological sciences*. 2006;248(1-2):62-7.
- [19] Ghebremedhin E, Del Tredici K, Vuksic M, et al. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology[J]. *Journal of neuropathology and experimental neurology*. 2006;65(2):116-23.
- [20] Blazquez L, Otaegui D, Saenz A, et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease[J]. *Neuroscience letters*. 2006;406(3):235-9.
- [21] Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations[J]. *Movement disorders : official journal of the Movement Disorder Society*. 2005;20(8):989-94.
- [22] Zhou Chang-wen XJ-t, Gui Jun-hao. Association between Polymorphism of Apolipoprotein E Gene and Parkinson's Disease[J]. *CARCINOGENESIS,TERATOGENESIS AND MUTAGENESIS*. 2004;1004-616X(chi):3.
- [23] Xiao-Ping Zhao W-WZ, Jun Feng, Hui-Jun Xie. Relationship of apolipoprotein E gene polymorphism to Parkinson's disease and Alzheimer's disease[J]. *CHINESE JOURNAL OF CLINICAL REHABILITATION*. 2003(31):2.

- [24] Schulte T, Bohringer S, Schols L, et al. Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease[J]. Journal of neural transmission. 2003;110(7):749-55.
- [25] Tang G, Xie H, Xu L, et al. Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease[J]. American journal of medical genetics. 2002;114(4):446-9.
- [26] Parsian A, Racette B, Goldsmith LJ, et al. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset[J]. Genomics. 2002;79(3):458-61.
- [27] Herz J, Bock HH. Lipoprotein receptors in the nervous system[J]. Annual review of biochemistry. 2002;71:405-34.
- [28] Wang Fen LM-L, Yang Zhi-Jie. Analysis the polymorphism of apolipoprotein E gene in patients of parkinson disease with dementia[J]. MODERN REHABILITATION. 2001(3):2.
- [29] Hao Y, Xie H, Xu L. [Association between polymorphism of alpha 1-antichymotrypsin and apolipoprotein E gene and Parkinson's disease in Shanghai Hans][J]. Zhonghua yi xue za zhi. 2001;81(19):1172-5.
- [30] Zeng Xiangyu GH, Qin Bin. The study of relationship between Alzheimer's and Parkinson's disease with dementia and apolipoprotein E polymorphism[J]. CHINESE GENERAL PRACTICE. 2000;1007-9572(5):3.
- [31] Harhangi BS, de Rijk MC, van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study[J]. Neurology. 2000;54(6):1272-6.
- [32] Zhang Jun-Hui PY-H, Li Jing-Ru CLINICAL SIGNIFICANCE OF EYE MOVEMENT ABNORMALITY IN BRAIN STEM LESION[J]. JOURNAL OF CLINICAL NEUROLOGY. 1999(1999,3):3.
- [33] Oliveri RL, Nicoletti G, Cittadella R, et al. Apolipoprotein E polymorphisms and Parkinson's disease[J]. Neuroscience letters. 1999;277(2):83-6.
- [34] Bon MA, Jansen Steur EN, de Vos RA, et al. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism[J]. Neuroscience letters. 1999;266(2):149-51.
- [35] Qin Bing ZX-Y, Guo Han-Bang. Analysis of Apolipoprotein E Genotype in Parkinson's Disease with or without Dementia.[J]. CHINESE JOURNAL OF NEUROLOGY. 1998;1006-7876(1998,3):3.
- [36] Apolipoprotein E genotype in familial Parkinson's disease. The French Parkinson's Disease Genetics Study Group[J]. Journal of neurology, neurosurgery, and psychiatry. 1997;63(3):394-5.
- [37] Ballering LA, Steffens-Nakken HM, Esselink RA, et al. Apolipoprotein E genotyping in patients with neurodegenerative diseases[J]. Clinical biochemistry. 1997;30(5):405-11.
- [38] Whitehead AS, Bertrand S, Finnane F, et al. Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease[J]. Journal of neurology, neurosurgery, and psychiatry. 1996;61(4):347-51.
- [39] Rubinsztein DC, Hanlon CS, Irving RM, et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease[J]. Molecular and cellular probes. 1994;8(6):519-25.